Free Trial
NASDAQ:IPSC

Century Therapeutics Q4 2024 Earnings Report

Century Therapeutics logo
$0.56 -0.02 (-3.00%)
As of 11:32 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Century Therapeutics EPS Results

Actual EPS
-$0.43
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Century Therapeutics Revenue Results

Actual Revenue
$4.18 million
Expected Revenue
$0.67 million
Beat/Miss
Beat by +$3.51 million
YoY Revenue Growth
N/A

Century Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 19, 2025
Conference Call Time
9:30AM ET

Century Therapeutics Earnings Headlines

Chardan Capital Issues Optimistic Forecast for IPSC Earnings
Leerink Partnrs Issues Pessimistic Outlook for IPSC Earnings
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
See More Century Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Century Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Century Therapeutics and other key companies, straight to your email.

About Century Therapeutics

Century Therapeutics (NASDAQ:IPSC), a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

View Century Therapeutics Profile

More Earnings Resources from MarketBeat